Regarding 'HPV Vaccination for Cervical Cancer Prevention is not Cost-effective in Japan'

DOI QR Code

Arakawa, Ichiro (Unit of Health Economics, Faculty of Pharmaceutical Science, Teikyo Heisei University) ;
Murasawa, Hideki (Unit of Health Economics, Faculty of Pharmaceutical Science, Teikyo Heisei University) ;
Konno, Ryo (Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University)

Boardman AE, Greenberg DH, VoningAR, et al (2011). Cost-Benefit Analysis Concept and Practice 4Th Edition Upper Saddle River. NJ, 408-13.
Drummond M, Sculpher MJ, Torrance GW, et al. (2005). Methods for Economic Evaluation of Health Care 3Rd Edition Oxford Press, NY, 31-34.
Drummond M, Jefferson TO (1996). Guideline for the authors and peer reviewers of economic submissions to the BMJ. BMJ, 313, 275-83. https://doi.org/10.1136/bmj.313.7052.275
Hamashima C, Aoki D, Miyagi E, et al (2010). The Japanese guidance for cervical cancer screening. Jpn J Cin Oncol, 40, 485-502. https://doi.org/10.1093/jjco/hyq036
Isshiki T (2014). HPV vaccination for cervical cancer prevention is not cost-effective in Japan. Asian Pac J Can Prev, 15, 6177-80. https://doi.org/10.7314/APJCP.2014.15.15.6177
Konno R, Sasagawa T, Fukuda T, et al (2010). Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Can, 20, 385-92. https://doi.org/10.1111/IGC.0b013e3181d189b8
OECD (2011). OECD health data.
Uchida A, Tango M, Hosokawa K, et al (2010). Cost-Benefit Analysis: Cervical Cancer Vaccination. [online]http://www.pp.u-tokyo.ac.jp/courses/2010/documents/